Ultralife Corp 8-K, filed Apr 27, 2020
Ultralife Corp (ULBI)
About this 8-K
Ultralife Corp filed this 8-K on April 27, 2020.
Items reported
- Item 8.01: Other events
| UNITED STATES | ||
|---|---|---|
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
| FORM 8-K | ||
| CURRENT REPORT<br><br> <br>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | ||
| April 2 7 , 2020 | ||
| Date of Report (Date of Earliest Event Reported) | ||
| ULTRALIFE CORPORATION | ||
| (Exact name of registrant as specified in its charter) | ||
| Delaware | 000-20852 | 16-1387013 |
| (State of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2000 Technology Parkway, Newark, New York 14513 | ||
| (Address of principal executive offices) (Zip Code) | ||
| (315) 332-7100 | ||
| (Registrant’s telephone number, including area code) | ||
| None | ||
| (Former name or former address, if changed since last report) | ||
| Securities registered pursuant to Section 12(b) of the Act: | ||
| Common Stock, $0.10 par value per share | ULBI | NASDAQ |
| (Title of each class) | (Trading Symbol) | (Name of each exchange on which registered) |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | ||
| ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br><br> <br><br><br> <br>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐<br><br> <br><br><br> <br>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Ite m 8.01 Other Events
Ultralife Corporation (the “Company”) is disclosing through this Current Report on Form 8-K that it is returning the $3,459,278 in proceeds from a loan provided by KeyBank National Association on April 16, 2020, which was granted pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act, and was not used by the Company, to ensure compliance with the FAQ’s and revised Guidelines issued by the U.S. Department of Treasury and the Small Business Administration on April 23, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April 27, 2020 | ULTRALIFE Corporation | |
|---|---|---|
| By: | /s/ Philip A. Fain | |
| Philip A. Fain | ||
| Chief Financial Officer and Treasurer |